Evosep, a Copenhagen, Denmark-based bioscience firm engaged on the standardization of proteomics for medical use, acquired $40M in funding.
The spherical was led by Novo Holdings. Given the funding, Stephen Van Helden, Principal, Novo Holdings, who relies in San Francisco, will be a part of Evosep’s Board of Directors.
The firm intends to make use of the funds to advance medical purposes of proteomics enabled by its standardized liquid chromatography platform, and additional develop its presence globally, particularly within the US market.
Founded in 2016 by proteomics know-how pioneer Ole Vorm, and led by CEO Christian Ravnsborg, Evosep goals to enhance high quality of life and affected person care by unlocking LC-MS for drug discovery and innovating how protein-based medical diagnostics are carried out throughout panels with a number of protein biomarkers. Its platform gives a high-sample-throughput functionality with reproducibility (i.e., useful, useable knowledge) between pattern runs and throughout devices and websites. The know-how shapes the potential of proteomics by growing useful purposes, enabling widespread use, and the event of clinically significant protein-based diagnostics.